Peptide cycling for women over 40: what the evidence says

What's this video probably claiming?

Based on the caption "Do you cycle your peppys?" and the hashtags pairing #glp1 with #biohacking and #womenover40, this creator is almost certainly walking viewers through a peptide cycling protocol, likely involving secretagogues like CJC-1295, ipamorelin, or MK-677, possibly alongside a GLP-1 receptor agonist. The framing around cycling, meaning rotating peptides on and off to avoid receptor desensitization or tolerance, is extremely common in biohacking circles targeting perimenopausal and postmenopausal women. The implicit claims are probably: cycling prevents your body from adapting to peptides, cycling improves outcomes compared to continuous use, and that this is a well-established practice. The audience being women over 40 suggests the creator may also be gesturing toward hormone optimization, body composition, or metabolic health benefits. These are real concerns for this demographic, but the way they get packaged in short-form video tends to skip over what the clinical evidence actually supports, and what it doesn't.

What does the science actually show?

The honest answer is: not much, at least not in humans, at least not on cycling specifically. The peptides most commonly discussed in this space, CJC-1295 and ipamorelin, have shown growth hormone pulse amplification in small clinical trials. A 2006 study by Jetté et al. in Growth Hormone and IGF Research demonstrated that CJC-1295 produced sustained GH elevation over days, not hours, which actually complicates the case for cycling. MK-677, an oral ghrelin mimetic, was studied in a randomized controlled trial by Nass et al. (2008, Annals of Internal Medicine) in 65 adults over 2 years and did increase IGF-1 levels, but also increased fasting glucose and insulin resistance, findings that rarely make it into TikTok videos. BPC-157 has compelling rodent data on tissue repair and gastroprotection, but zero completed human RCTs as of 2024. The cycling rationale itself, avoiding tachyphylaxis, has theoretical support from endocrinology but no peptide-specific human trial has compared cycled versus continuous protocols on meaningful outcomes like lean mass retention or metabolic markers.

Where does the social media noise diverge from clinical reality?

Several places, and the gaps are significant. First, cycling schedules circulating online, typically 5 days on, 2 days off, or 8 weeks on, 4 weeks off, are not derived from published pharmacokinetic data. They are gym-culture conventions borrowed from anabolic steroid lore and applied to peptides without the same biological rationale. Second, the GLP-1 hashtag paired with peptide cycling implies these may be stacked, which raises real questions. GLP-1 agonists already affect gastric motility, appetite signaling, and insulin secretion. Adding growth hormone secretagogues to that mix has not been studied in combination, and the metabolic interactions are genuinely unknown. Third, the framing around women over 40 as a special population is partially valid, perimenopause does alter GH pulsatility and IGF-1 levels, but the specific protocols being promoted are extrapolated from mostly male or mixed cohorts. A 2019 review by Sigalos and Pastuszak in Current Urology Reports noted that peptide use in aging populations lacks sex-stratified safety data.

What should you actually know?

If you are considering peptide therapy, the cycling question is less important than the sourcing and oversight questions. In the United States, most peptides discussed in this context are not FDA-approved drugs. They exist in a regulatory gray zone, often compounded, and quality control between suppliers varies enormously. A 2023 analysis by Cohen et al. in JAMA Internal Medicine found that peptide products sold through wellness channels frequently contained inaccurate labeled doses or unlisted compounds. MK-677 specifically carries a warning in the Nass trial data about glucose dysregulation, which is directly relevant for perimenopausal women already at elevated metabolic risk. BPC-157 has no human dose-safety data at all. Any creator presenting a cycling protocol as established or optimized practice is working well ahead of the clinical literature. That does not make peptide therapy categorically wrong, but it does mean these decisions belong in a conversation with a licensed clinician who can review your bloodwork, not in a TikTok comment section.